DE69331005T2 - Verbindung zur biologischen stimulation und korrektur des phenotyps eines organismus und verfahren für ihre herstellung - Google Patents
Verbindung zur biologischen stimulation und korrektur des phenotyps eines organismus und verfahren für ihre herstellungInfo
- Publication number
- DE69331005T2 DE69331005T2 DE69331005T DE69331005T DE69331005T2 DE 69331005 T2 DE69331005 T2 DE 69331005T2 DE 69331005 T DE69331005 T DE 69331005T DE 69331005 T DE69331005 T DE 69331005T DE 69331005 T2 DE69331005 T2 DE 69331005T2
- Authority
- DE
- Germany
- Prior art keywords
- composition
- amount
- composition according
- sugar
- additive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000012937 correction Methods 0.000 title claims description 9
- 230000000638 stimulation Effects 0.000 title claims description 7
- 238000000034 method Methods 0.000 title description 15
- 239000000203 mixture Substances 0.000 claims description 111
- 235000002639 sodium chloride Nutrition 0.000 claims description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- 239000011780 sodium chloride Substances 0.000 claims description 21
- 239000000654 additive Substances 0.000 claims description 19
- 230000000996 additive effect Effects 0.000 claims description 15
- 235000000346 sugar Nutrition 0.000 claims description 14
- 235000012907 honey Nutrition 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 6
- 230000005684 electric field Effects 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 150000003841 chloride salts Chemical class 0.000 claims description 3
- 235000013681 dietary sucrose Nutrition 0.000 claims description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 239000010941 cobalt Substances 0.000 claims description 2
- 229910017052 cobalt Inorganic materials 0.000 claims description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 229910052750 molybdenum Inorganic materials 0.000 claims description 2
- 239000011733 molybdenum Substances 0.000 claims description 2
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical class Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 43
- 201000010099 disease Diseases 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 229910052751 metal Inorganic materials 0.000 description 9
- 239000002184 metal Substances 0.000 description 9
- 150000002739 metals Chemical class 0.000 description 9
- 201000004384 Alopecia Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 208000024963 hair loss Diseases 0.000 description 7
- 230000003676 hair loss Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000934856 Daphne Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000011278 mitosis Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000002636 symptomatic treatment Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010011985 Decubitus ulcer Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000001752 female genitalia Anatomy 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000000260 male genitalia Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910001514 alkali metal chloride Inorganic materials 0.000 description 1
- 229910001617 alkaline earth metal chloride Inorganic materials 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000005669 field effect Effects 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000005082 stem growth Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 208000025421 tumor of uterus Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/08—Mineral waters; Sea water
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU9292003081A RU2093180C1 (ru) | 1992-10-30 | 1992-10-30 | Состав для биологической стимуляции организма и способ его обработки |
| RU9292005267A RU2093181C1 (ru) | 1992-11-10 | 1992-11-10 | Состав для биологической стимуляции организма |
| RU9393008264A RU2093182C1 (ru) | 1993-02-15 | 1993-02-15 | Состав для биологической стимуляции организма |
| PCT/RU1993/000189 WO1994009797A1 (en) | 1992-10-30 | 1993-08-09 | Compound for the biological stimulation and correction of the phenotype of an organism and a process for producing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69331005D1 DE69331005D1 (de) | 2001-11-29 |
| DE69331005T2 true DE69331005T2 (de) | 2002-06-06 |
Family
ID=27354124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69331005T Expired - Fee Related DE69331005T2 (de) | 1992-10-30 | 1993-08-09 | Verbindung zur biologischen stimulation und korrektur des phenotyps eines organismus und verfahren für ihre herstellung |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPH07502764A (ja) |
| KR (1) | KR100301340B1 (ja) |
| DE (1) | DE69331005T2 (ja) |
| DK (1) | DK0633027T3 (ja) |
| ES (1) | ES2164668T3 (ja) |
| PT (1) | PT633027E (ja) |
| WO (1) | WO1994009797A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000078349A1 (fr) * | 1999-06-18 | 2000-12-28 | Pascal Berdal | Procede pour l'obtention de produits ayant des effets benefiques |
| FR2800575B1 (fr) * | 1999-11-08 | 2003-01-24 | Pascal Berdal | Procede pour preparer des aliments et des complements alimentaires ayant des effets sur la sante |
| EP1666049A4 (en) * | 2003-08-07 | 2008-04-30 | Gennadij A Markov | MARKOV THERAPEUTIC AND PROPHYLACTIC COMPOSITION |
| KR102548082B1 (ko) | 2020-11-26 | 2023-06-26 | 한국화학연구원 | 기상 증착을 이용한 고밀도의 균일한 나노 입자 합성 방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2952592A1 (de) * | 1979-12-28 | 1981-07-02 | Werner 6751 Trippstadt Kropp | Herstellung von arzneimitteln und von mitteln zur unschaedlichmachung von mikroorganismen |
| IT1132508B (it) * | 1980-07-04 | 1986-07-02 | Franco Donadelli | Metodo per l'incremento dei processi metabolici degli epitelli mediante applicazione biochimica d'un campo elettrico |
| DE3585368D1 (de) * | 1984-06-22 | 1992-03-19 | Richard L Veech | Polyanionische materialien enthaltende elektrolytloesungen. |
| US4767611A (en) * | 1984-07-03 | 1988-08-30 | Gordon Robert T | Method for affecting intracellular and extracellular electric and magnetic dipoles |
| JPH04500505A (ja) * | 1988-05-02 | 1992-01-30 | クライオメディカル サイエンシズ インコーポレイティド | 代用血液 |
| FR2640510B1 (fr) * | 1988-12-20 | 1991-10-31 | Therabion Sa Laboratoires | Oligo-elements actives, leur procede de preparation et les compositions les renfermant, utiles pour la sante |
| US5188738A (en) * | 1990-08-06 | 1993-02-23 | Steven Kaali | Alternating current supplied electrically conductive method and system for treatment of blood and/or other body fluids and/or synthetic fluids with electric forces |
| CA2066374C (en) * | 1991-04-19 | 2002-01-29 | Paul E. Segall | Solution for perfusing primates |
-
1993
- 1993-08-09 KR KR1019940702303A patent/KR100301340B1/ko not_active IP Right Cessation
- 1993-08-09 DK DK93919734T patent/DK0633027T3/da active
- 1993-08-09 DE DE69331005T patent/DE69331005T2/de not_active Expired - Fee Related
- 1993-08-09 JP JP6510936A patent/JPH07502764A/ja active Pending
- 1993-08-09 ES ES93919734T patent/ES2164668T3/es not_active Expired - Lifetime
- 1993-08-09 WO PCT/RU1993/000189 patent/WO1994009797A1/ru active IP Right Grant
- 1993-08-09 PT PT93919734T patent/PT633027E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK0633027T3 (da) | 2001-12-10 |
| JPH07502764A (ja) | 1995-03-23 |
| PT633027E (pt) | 2002-03-28 |
| KR100301340B1 (ko) | 2001-10-22 |
| DE69331005D1 (de) | 2001-11-29 |
| KR940703679A (ko) | 1994-12-12 |
| ES2164668T3 (es) | 2002-03-01 |
| WO1994009797A1 (en) | 1994-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH662945A5 (de) | Ophthalmische loesung. | |
| WO2008138305A1 (de) | Stimulationsvorrichtung zur behandlung von suchtkrankheiten | |
| EP0326826B1 (de) | Mittel mit zerstörender Wirkung auf maligne Tumore, Verfahren zu dessen Herstellung und Präparation zur Anwendung in der Therapie von Krebskranken | |
| DE69615984T2 (de) | Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen | |
| Schwarzacher | Der Cholinesterasegehalt motorischer Nervenzellen während der axonalen Reaktion | |
| EP0002495B1 (de) | Erzeugnisse zur Anwendung in der cytostatischen Therapie | |
| DE3424781A1 (de) | Verwendung von l-carnosin zur tumorbehandlung | |
| DE69331005T2 (de) | Verbindung zur biologischen stimulation und korrektur des phenotyps eines organismus und verfahren für ihre herstellung | |
| CH670952A5 (ja) | ||
| DE69626816T2 (de) | Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren | |
| EP0334243B1 (de) | Arzneimittel enthaltend Aminoacridine zur iontophoretischen Behandlung von Carcinomen | |
| DE69330638T2 (de) | Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem | |
| DE4240713C1 (de) | Verwendung eines Gemischs aus Calciumhydroxid und Oleum pedum tauri zur Kollageneubildung in vivo | |
| AT408719B (de) | Mittel zur behandlung von hepatitis c | |
| EP0633027B1 (en) | Compound for the biological stimulation and correction of the phenotype of an organism and a process for producing the same | |
| DE19828068C2 (de) | Mittel zur spezifischen Hemmung osteoklastärer Knochenresorption | |
| AT234277B (de) | Verfahren zur Herstellung oral verabreichbarer Eisenpräparate | |
| Voirol | III. Über unsere klinischen Erfahrungen mit synthetisch dargestellten Wehenmitteln | |
| DE3513391A1 (de) | Neues nootropikum | |
| DE60210400T2 (de) | Die Wirkung eines Puffers auf die Säurebildung durch Plaque | |
| DE3844518A1 (de) | Verwendung von aminochinolinen und aminopyridinen zur iontophoretischen behandlung maligner tumore | |
| RU2093183C1 (ru) | Состав для биологической стимуляции организма | |
| Polterauer | Präoperativ elektrisch evozierte Hirnstammpotentiale als Prädiktor des postoperativen Verlaufs nach einer Cochleaimplantation | |
| DE10215753A1 (de) | Verwendung von Pyrimidinnukleotiden zur Behandlung von Schädigungen des peripheren Nervensystems | |
| DE10117615A1 (de) | Verwendung von Nucleosiden, Nucleobasen und deren Derivaten zur verbesserten Gewinnung von adulten Stammzellen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |